ARTICLE | Company News
CV Tech, Shield deal
April 19, 1999 7:00 AM UTC
SDG will exclusively develop and market, except in Japan, CV's parathyroid hypertensive factor (PHF) test kit to manage hypertension. SDG will pay CV a $30,000 upfront fee, and is responsible for clin...